Sysmex Corporation ADR (OTCMKTS:SSMXY – Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $8.98, but opened at $9.48. Sysmex shares last traded at $9.46, with a volume of 1,767 shares trading hands.
Analysts Set New Price Targets
Separately, Citigroup lowered shares of Sysmex from a “strong-buy” rating to a “hold” rating in a report on Monday, March 16th. One analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold”.
View Our Latest Analysis on SSMXY
Sysmex Stock Performance
Sysmex (OTCMKTS:SSMXY – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.02). The firm had revenue of $877.92 million for the quarter, compared to analysts’ expectations of $862.45 million. Sysmex had a return on equity of 7.23% and a net margin of 7.13%.Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. As a group, research analysts expect that Sysmex Corporation ADR will post 0.42 earnings per share for the current fiscal year.
Sysmex Company Profile
Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.
The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.
Read More
- Five stocks we like better than Sysmex
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
- General Mills Is a 5-Star Turnaround Play for Buy and Hold Investors
- Agility Robotics’ SPAC Deal Opens a Rare Door Into Humanoid AI
Receive News & Ratings for Sysmex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sysmex and related companies with MarketBeat.com's FREE daily email newsletter.
